P

PharmaEssentia
6446

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
NT$182.63B
EV
NT$161.58B
Shares Outstanding
334.51M
Beta
-0.08

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
NT$700.50
P/E 2025E
35.99x
P/Revenue 2025E
11.68x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About PharmaEssentia Corporation

gainify

P

PharmaEssentia Corporation

6446

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibr...

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Lin, Ko-Chung

Employees

131

IPO Date

2014-03-11

Headquarters

No. 3, Park Street, 2nd-5th Floor, Nangang District, Taipei 115, Taiwan

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.